# Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

> **NCT03835871** · PHASE3 · WITHDRAWN · sponsor: **Adamis Pharmaceuticals Corporation**

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** 400 µg per day Beclomethasone
- **DRUG:** 200 µg per day Beclomethasone
- **DRUG:** 100 µg per day Beclomethasone

## Key facts

- **NCT ID:** NCT03835871
- **Lead sponsor:** Adamis Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-02
- **Primary completion:** 2019-12
- **Final completion:** 2020-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2019-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03835871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03835871, "Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03835871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*